By Indication

Invasive Fungal Infection (IFI) Market Analysis

Cross-industry research covering Invasive Fungal Infection (IFI) across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Invasive Fungal Infection (IFI)

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

IFI in immunocompromised inpatients, particularly post-allogeneic HCT recipients (nct:NCT05470491), drives echinocandin and extended-spectrum azole demand. Azole resistance propagation (nct:NCT06532227) is actively narrowing the effective antifungal formulary, which will structurally elevate per-episode drug cost for affected patient cohorts.

12%

Market Share

7.4%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments